Effect of Preoperative Tramadol and Naproxen Sodium on Post Operative Pain

NCT ID: NCT05982392

Last Updated: 2024-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-01

Study Completion Date

2023-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to compare in Tramadol, Naproxen sodium and Placebo in participants presenting with irreversible pulpitis in their mandibular posterior teeth.

The main question\[s\] it aims to answer are:

* Local anesthetic efficacy and .
* Postoperative pain. Participants will receive premedication treatments 60 minutes prior to the local anesthesia administration.

Researchers will compare Tramadol, Naproxen sodium and Placebo to evaluate their effects on Inferior alveolar nerve block efficacy and Postoperative pain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The adult participants who report in out-patient department (OPD) of Operative Dentistry at Dow International Dental College with the symptoms of irreversible pulpitis will be screened for the participation in the study. A detailed history will be taken which will be followed by clinical examination and complemented with sensibility testing with Endo Ice or electric pulp test. Radiographic analysis will also be done to confirm the diagnosis to assess for factors pertaining to exclusion and inclusion criteria. Verbal and written informed consent will be taken from all the participants.

Randomization: The participants will be randomly divided into 3 groups by envelope method.

Group A will receive premedication of Oral tramadol 100mg, Group B will receive premedication of oral naproxen 550mg. Both medicines will be given 60 minutes prior to the local anesthesia administration. The third group, Group C, will be the control group and no active preoperative medication will be given to these participants. A placebo will be given to these participants. These medications will be given as a single intervention only.

Blinding: Clinician and participants both will be blind to the medicine given to the participants. Participants will be allowed to pick envelopes and a paramedical staff will be trained in giving medication to the participants.

Pain scores will be recorded by asking the participant to rate their pain on a scale ranging from 0 to 10 before medication and then after 15 minutes, 30 minutes and 60 minutes of administering the premedication. Pain score will also be recorded after 10 minutes of the administration of Inferior alveolar nerve block (IANBs) and buccal nerve block \& during deroofing process of chamber opening.

Two cartridges of Lidocaine 1.8 ml having a concentration of 1:100,000 of Epinephrine will be used for administration of regional anesthesia. Access opening will be performed under rubber dam isolation with a Mani number 245 bur in a high-speed hand piece with copious water irrigation. Sodium hypochlorite (5.25%) will be used as a standard root canal irrigation solution.Pulpectomy will be performed with Mani K-files (8-25) till respective working lengths of the teeth under study.

To assess the post-operative pain, a proforma and pain intensity scale will be provided to the participants for self recording at 6, 24, 48 and 72 hours after the procedure. The participants will return the proforma to an intern on 3rd day to be assessed by an intern supervised by the principal investigator.

(For this research, "The investigators will be offering As per need analgesic for breakthrough pain. Participants will be offered brufen 400mg as needed. The participants will be advised to mark breakthrough pain on VAS at the time of taking medicine).

The participants will also be monitored for the adverse effects of these medications (nausea, vomiting, dizziness, drowsiness) as a secondary outcome .at above-mentioned time-intervals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Symptomatic Irreversible Pulpitis Post Operative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The participants will be randomly divided into 3 groups by envelope method. Group A will receive premedication of Oral tramadol 100mg, Group B will receive premedication of oral naproxen sodium 550mg. Both medicines will be given 60 minutes prior to the local anesthesia administration. The third group, Group C, will be the control group and no active preoperative medication will be given to these participants. A placebo will be given to these participants. These medications will be given as a single intervention only.
Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Clinician and participants both will be blind to the medicine given to the participants. Participants will be allowed to pick envelopes and a paramedical staff will be trained in giving medication to the participants. Procedure will be performed by an intern (who is not part of the research)Investigator will also be masked to the treatment being provided Outcome Assessor will be an intern who is not on research.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tramadol

Group A will receive premedication of Oral tramadol 100mg,

Group Type ACTIVE_COMPARATOR

Tramadol

Intervention Type DRUG

Tramadol 100mg will be given 60 minutes before start of procedure.

Naproxen Sodium

Group B will receive premedication of oral naproxen sodium 550mg.

Group Type ACTIVE_COMPARATOR

Naproxen Sodium

Intervention Type DRUG

Naproxen sodium 550mg will be given 60 minutes before start of procedure.

Placebo

Group C, will be the control group and no active preoperative medication will be given to these patients.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be given 60 minutes before start of procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tramadol

Tramadol 100mg will be given 60 minutes before start of procedure.

Intervention Type DRUG

Naproxen Sodium

Naproxen sodium 550mg will be given 60 minutes before start of procedure.

Intervention Type DRUG

Placebo

Placebo will be given 60 minutes before start of procedure.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tramal tablet Synflex 550mg Surbex Z

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA I and ASA II individuals who are between the ages of 18 and 60 years.
* Patients who have been diagnosed with symptomatic irreversible pulpitis (with either a normal periapex or symptomatic apical periodontitis).
* Patients who score moderate to severe (4-10) on a preoperative visual analogue scale (VAS= 1-10).
* Mandibular permanent premolar and molars.

Exclusion Criteria

* Patients who had taken painkillers or narcotics in the previous 12 hours
* Patients suffering from severe pain because of traumatic occlusion.
* Teeth with extensive damage, calcified canals, root resorption, and an open apex.
* Previously root canal treated teeth.
* Medically compromised patients (ASA-III and above)
* Those with special communication needs or who do not understand Urdu or English language.
* Pregnant and lactating women
* Individual patients who will be driving back alone
* Patients who are allergic to the prescribed medicines
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dow University of Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tayyaba Tahira

Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tayyaba Tahira, BDS FCPS

Role: PRINCIPAL_INVESTIGATOR

Dow International Dental College, Dow University of Health Sciences

Farah Naz, BDS FCPS

Role: STUDY_DIRECTOR

Dow International Dental College, Dow University of Health Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dow International Dental College

Karachi, Sindh, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2889

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.